New solutions for type 2 diabetes mellitus: The role of pioglitazone

PharmacoEconomics

Volumn 20, Issue SUPPL. 1, 2002, Pages 1-9

  Grossman, L D ^a,b,c  

^a Clinical Research   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CHOLESTEROL; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

CANADA; CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; HEALTH CARE SYSTEM; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; STATISTICAL ANALYSIS;

EID: 0036261510     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200220001-00001     Document Type: Review

References (31)

1. Clinical practice guidelines for the management of diabetes in Canada
2. The triumvirate: β-cell, muscle, liver: A collusion responsible for NIDDM
3. Insulin resistance and its consequences: Non-insulin dependent diabetes mellitus and coronary heart disease
4. Insulin resistance in non-insulin dependent, type II diabetes
5. Glucose transporters and insulin action - Implications for insulin resistance and diabetes mellitus
6. Pharmacologic therapy for type 2 diabetes mellitus
7. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus
8. Review: PPAR, the ultimate thrifty gene
9. Peroxisome proliferator-activated receptors: Nuclear control of metabolism
10. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone
11. Non-hypoglycemic effects of thiazolidinediones
12. The hormone resistin links obesity to diabetes
13. How pioglitazone affects glucose and lipid metabolism
14. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone
15. Clinical pharmacokinetics of pioglitazone
16. Pharmacokinetics of pioglitazone in patients with renal impairment
17. In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: Comparison with pioglitazone and rosiglitazone
18. Pioglitazone has low potential for drug interactions
19. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes
20. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus
21. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in the treatment of patients with type 2 diabetes mellitus: A randomized placebo-controlled study
22. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: A randomized, placebo-controlled study
23. Combination therapy with pioglitazone and insulin in patients with type 2 diabetes
24. Homeostasis model assessment: Insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man
25. Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin- 1 and albumin excretion in diabetes patients
26. Safety and tolerability of pioglitazone
27. The relationship of HbA1c and weight in the treatment of patients with type 2 diabetes
28. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in patients with type 2 diabetes mellitus
29. Thiazolidinedione hepatotoxicity: A class effect?